The global immunomodulators market size reached US$ 211.2 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 331.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.13% during 2023-2032.
Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines, levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).
Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.
Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines, levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).
Immunomodulators Market Trends:
The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide.Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global immunomodulators market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.Breakup by Product:
- Immunosuppressants
- Antibodies
- Calcineurin Inhibitors
- Glucocorticoids
- Antimetabolites
- Others
- Immunostimulants
- Vaccines
- Antibodies
- Others
Breakup by Application:
- Oncology
- Respiratory
- HIV
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.Key Questions Answered in This Report:
- How has the global immunomodulators market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global immunomodulators market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global immunomodulators market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Immunomodulators Market
6 Market Breakup by Product
7 Market Breakup by Application
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly
- Company
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 211.2 Billion |
| Forecasted Market Value ( USD | $ 331.4 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
